SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CASTELLAZZI, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.189
AS - Asia 7.287
EU - Europa 3.975
SA - Sud America 1.057
AF - Africa 167
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 14
Totale 25.718
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.893
SG - Singapore 2.774
CN - Cina 1.824
IT - Italia 831
BR - Brasile 823
VN - Vietnam 786
HK - Hong Kong 597
DE - Germania 548
UA - Ucraina 543
PL - Polonia 475
GB - Regno Unito 418
TR - Turchia 385
FI - Finlandia 300
FR - Francia 212
BD - Bangladesh 198
JP - Giappone 183
SE - Svezia 165
CA - Canada 155
RU - Federazione Russa 153
IN - India 137
MX - Messico 97
ID - Indonesia 86
AR - Argentina 80
ZA - Sudafrica 68
AT - Austria 66
IQ - Iraq 63
NL - Olanda 60
CZ - Repubblica Ceca 40
CO - Colombia 37
BE - Belgio 33
ES - Italia 33
PK - Pakistan 33
EC - Ecuador 28
UZ - Uzbekistan 27
AU - Australia 26
VE - Venezuela 26
IR - Iran 23
MA - Marocco 21
SA - Arabia Saudita 21
PY - Paraguay 20
PH - Filippine 18
CL - Cile 17
EG - Egitto 17
LT - Lituania 17
AE - Emirati Arabi Uniti 14
KR - Corea 14
KE - Kenya 13
IE - Irlanda 12
NP - Nepal 12
ET - Etiopia 10
KZ - Kazakistan 10
MY - Malesia 10
PE - Perù 10
UY - Uruguay 10
DZ - Algeria 9
JO - Giordania 9
A2 - ???statistics.table.value.countryCode.A2??? 8
AZ - Azerbaigian 8
IL - Israele 8
JM - Giamaica 8
PT - Portogallo 8
RO - Romania 8
TN - Tunisia 8
AL - Albania 7
HN - Honduras 7
EU - Europa 6
HR - Croazia 6
LB - Libano 6
TH - Thailandia 6
AO - Angola 5
BG - Bulgaria 5
BO - Bolivia 5
BH - Bahrain 4
BY - Bielorussia 4
CR - Costa Rica 4
KG - Kirghizistan 4
MD - Moldavia 4
PS - Palestinian Territory 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
DO - Repubblica Dominicana 3
GR - Grecia 3
GT - Guatemala 3
HU - Ungheria 3
LV - Lettonia 3
LY - Libia 3
MN - Mongolia 3
NZ - Nuova Zelanda 3
OM - Oman 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
SY - Repubblica araba siriana 3
BB - Barbados 2
CH - Svizzera 2
CI - Costa d'Avorio 2
CY - Cipro 2
DK - Danimarca 2
GE - Georgia 2
Totale 25.686
Salva come PNG Salva come JPEG
Città #
Singapore 1.691
Ashburn 1.629
Woodbridge 1.121
San Jose 991
Fairfield 905
Chandler 714
Houston 600
Beijing 599
Hong Kong 590
Jacksonville 563
Santa Clara 553
Warsaw 459
Ann Arbor 391
Seattle 335
Wilmington 328
New York 325
Cambridge 295
Ho Chi Minh City 258
Los Angeles 258
Dallas 257
Ferrara 232
Izmir 223
Nanjing 187
Hanoi 180
Tokyo 178
Princeton 153
Milan 150
Council Bluffs 145
Lauterbourg 132
Munich 132
Helsinki 120
Boardman 110
Shanghai 95
San Diego 87
São Paulo 87
Buffalo 81
Dearborn 78
Orem 76
The Dalles 71
Addison 65
London 61
Mexico City 61
Jakarta 60
Turku 57
Brooklyn 55
Nanchang 55
Toronto 54
Tianjin 53
Montreal 51
Vienna 51
Shenyang 48
Bremen 47
Chennai 47
Chicago 43
Changsha 42
Hebei 42
Jiaxing 42
Phoenix 42
Atlanta 41
Denver 41
Norwalk 38
Stockholm 36
Hefei 34
Johannesburg 34
Brussels 33
Frankfurt am Main 33
Haiphong 33
Poplar 31
Baghdad 30
Bologna 30
Brno 29
San Francisco 29
Falls Church 27
Boston 26
Moscow 26
Da Nang 24
Manchester 24
Tashkent 24
Rome 23
Guangzhou 22
Redwood City 22
Zhengzhou 22
Amsterdam 21
Nuremberg 21
San Mateo 21
Dong Ket 20
Jinan 20
Ningbo 20
Rio de Janeiro 20
Auburn Hills 19
Biên Hòa 19
Orange 19
Belo Horizonte 18
Brasília 18
Mountain View 17
Washington 17
Ankara 16
Columbus 16
Shenzhen 16
Falkenstein 15
Totale 17.400
Salva come PNG Salva come JPEG
Nome #
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment 415
Decreased Arylesterase activity of Paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases 302
Autophagy and mitophagy elements are increased in body fluids of multiple sclerosis-affected individuals 300
A Commentary on the Use of Epstein-Barr Virus Specific Antibodies as Biological Markers in Multiple Sclerosis 284
Multiple Sclerosis in Italy: A 40-Year Follow-Up of the Prevalence in Ferrara 280
Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker 256
Epstein-Barr virus and Multiple Sclerosis: in-depth analysis of the virus-specific antibody response at the time of diagnosis and during therapy 254
Timing of serum active MMP-9 and MMP-2 levels in acute and subacute phases after spontaneous intracerebral hemorrhage 252
Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients 252
Chlamydia pneumoniaespecific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms 251
TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis 251
Comparison of antibodies with amylase activity from cerebrospinal fluid and serum of patients with multiple sclerosis 241
Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis 239
Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimer's disease and mild cognitive impairment 238
Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules 238
Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis 234
Detection of antibodies directed against human herpesvirus 6 U94/REP in sera of patients affected by multiple sclerosis 229
Emerging topics and new perspectives on HLA-G 224
Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis 224
Assessment of HIV-intrathecal humoral immune response in AIDS-related neurological disorders 223
Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies 221
Epidemiological health and social study on multiple sclerosis in the Ferrara province 218
Comparison of DNA-Hydrolyzing Antibodies from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis 218
Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients 218
A Further Evidence Of Pathogenic Role Of Chlamydia Pneumoniae In Multiple Sclerosis 214
A proteomic approach to detect gelatinases levels and their inhibitors in patients with neurological diseases 214
Altered miRNA expression in T regulatory cells in course of multiple sclerosis 212
A new developed culture method efficiently supports the growth of Chamydia pneumoniae in PBMC and CSF samples from patients with Multiple Sclerosis 212
Affinity distribution of anti-EBV IgG in the cerebrospinal fluid of patients with multiple sclerosis and in controls 207
Cerebrospinal fluid analysis and the determination of oligoclonal bands 207
An overview on the relationship between Epstein-Barr virus and multiple sclerosis 205
Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis 205
CEREBROSPINAL FLUID AND SERUM LEVELS OF ANTI-CHLAMYDIA PNEUMONIAE IGA IN PATIENTS WITH MULTIPLE SCLEROSIS 204
Effect of pH on MMP-9 release by LPS-stimulated neutrophils 203
25-hydroxyvitamin D in cerebrospinal fluid from patients with multiple sclerosis 201
Matrix metalloproteinase 9 as a marker of disease activity in multiple sclerosis 198
Correlation between auto/mitophagic processes and magnetic resonance imaging activity in multiple sclerosis patients 194
Clinical and MRI activity are associated to elevated cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-9 in multiple sclerosis patients 193
Neurofilament ELISA validation 193
Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis 193
Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy 189
Quantification of CSF and serum levels and intrathecal synthesis of anti-EBV antibodies in patients with multiple sclerosis and with other neurological disorders. 189
DNA Sequences of Parachlamydia-like organisms in CSF of Patients with Neurological Disorders 187
Increased age and male sex are independently associated with higher frequency of blood-cerebrospinal fluid barrier dysfunction using the albumin quotient 187
ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR IMPLEMENTING A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES Identification of a TIMP-1-resistant active MMP-9 in serum of Multiple Sclerosis patients 185
Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings 183
Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding 182
Altered miRNA expression in T regulatory cells in course of multipla sclerosis 182
Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study 182
Intrathecal Soluble HLA-E Correlates with Disease Activity in Patients with Multiple Sclerosis and may Cooperate with Soluble HLA-G in the Resolution of Neuroinflammation. 182
ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR THE IMPLEMENTATION A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES IN MS. 180
Matrix metalloproteinase-9 activity detected in body fluids is the result of two different enzyme forms 177
Detection of Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response in a subset of patients with progressive forms of multiple sclerosis 176
Multiplex Matrix Metalloproteinases Analysis in the Cerebrospinal Fluid Reveals Potential Specific Patterns in Multiple Sclerosis Patients 176
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 are elevated in in multiple sclerosis patients with disease activity 176
Analysis of MMP-9 in CSF and sera of patients with neurological diseases 173
25 hydroxyvitamin D in cerebrospinal fluid from patients with multiple sclerosis during relapse and remission 172
CSF levels and soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis 170
Timing of Serum Soluble HLA-G Levels in Acute and Subacute Phases After Spontaneous Intracerebral Hemorrhage 168
Dimethyl Fumarate Treatment Reduces the Amount but Not the Avidity of the Epstein–Barr Virus Capsid-Antigen-Specific Antibody Response in Multiple Sclerosis: A Pilot Study 167
Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis 167
Elevated CSF and serum levels and intrathecal synthesis of active MMP-2 in MS patients with no evidence of MRI disease activity 166
CEREBROSPINAL FLUID AND SERUM LEVELS OF ANTI-CHLAMYDIA PNEUMONIAE IGA IN PATIENTS WITH MULTIPLE SCLEROSIS - ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR IMPLEMENTING A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES. 166
Biomolecular and immunological diagnostic aspects of toxoplasmosis during AIDS. 164
Intrathecal levels of vitamin D and IgG in multiple sclerosis 161
Specific antibodies reacting to JC polyomavirus capsid protein mimotopes in sera from multiple sclerosis and other neurological diseases-affected patients 161
An evaluation of quantitative env and qualitative pol rt-pcr detection of the multiple sclerosis (MS) -associated retrovirus in Europe 160
The Diagnostic Utility of Oligoclonal Bands in Multiple Sclerosis: A Time-Course Analysis 159
EBV-specific intrathecal oligoclonal antibody response in multiple sclerosis patients 157
N-acetylaspartate, glutammate and aspartate levels in multiple sclerosis cerebrospinal fluid. 156
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis 153
Increased Levels of Endothelin-1 in Cerebrospinal Fluid Are a Marker of Poor Visual Recovery after Optic Neuritis in Multiple Sclerosis Patients 153
Decrease Paraoxonase-1 (PON-1) Activities in Neurodegenerative Diseases 151
Cerebrospinal fluid oligoclonal free light chain profiles in AIDS 150
Effect of HLA-G gene polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosis. 150
Cerebrospinal Fluid Analysis in Rheumatological Diseases with Neuropsychiatric Complications and Manifestations: A Narrative Review 148
Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms 148
An evaluation of quantitative env and qualitative pol rt-pcr detection of the multiple sclerosis (MS) -associated retrovirus in Europe 148
Matrix metalloproteinases (MMP): determination of different forms by different techniques may require different preanalytical strategies 147
Herpesvirus Infections in KIR2DL2-Positive Multiple Sclerosis Patients: Mechanisms Triggering Autoimmunity 147
Sex Differences in Albumin Quotient and Cerebrospinal Fluid Total Protein Content Do Not Depend on Anthropometric Factors 146
Aspetti diagnostici biomolecolari ed immunologici della toxoplasmosi in pazienti AIDS. 145
Cerebrospinal fluid free Kappa and Lambda lights chains in MS. A qualitative analysis 144
CSF levels of soluble classical HLA-I and non-classical HLA-G molecules in relapsing-remitting multiple sclerosis and their association with CSF IL-10 concentrations and MRI findings. 144
Influence of different strategies of volume replacement on the activity of matrix metalloproteinases: an in vitro and in vivo study 143
INTRATHECAL PRODUCTION OF ACTIVE FORM OF MATRIX METALLOPROTEINASES-9 IN PATIENTS WITH MULTIPLE SCLEROSIS: PRELIMINARY RESULTS” 143
Gelatinase: enzymatic activity as potential biomarker in multiple sclerosis 142
Low prevalence of antibodies against Simian Virus 40 in serum samples from patients affected by neurologic diseases, including multiple sclerosis 140
Sex-Related Differences in Cerebrospinal Fluid Plasma-Derived Proteins of Neurological Patients 140
SERUM GELATINASES LEVELS IN MULTIPLE SCLEROSIS PATIENTS DURING 21 MONTHS OF NATALIZUMAB TREATMENT 138
Chlamydia pneumonia-specific CFS-restricted oligoclonal IgG bands are associated to a subset of patients with prosessive forms of multiple sclerosis. 137
Matrix Metalloproteinases as a Pleiotropic Biomarker in Medicine and Biology 137
Ruolo dei micro RNA nel funzionamento delle cellule T immunoregolatorie CD4 e CD25 nell'ambito della Sclerosi Multipla 136
Inflammation and axonal damage biomarkers in Multiple Sclerosis: new perspective on their role 135
Intrathecal synthesis of interleukin-12 in multiple sclerosis 133
Gelatinases: enzymatic activity as potential biomarker in multiple sclerosis 133
Sexual dimorphism in the cerebrospinal fluid total protein content 131
MMP-9 isoforms in serum of Multiple Sclerosis patients 129
Potential role of soluble HLA-G molecules in multiple sclerosis 129
Extracellular pH modulates the release of Matrix Metalloproteinase-9 (MMP-9) by stimulated neutrophils and its activity. 129
Totale 18.766
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.629
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.197
Totale 115.826
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.327 34 162 74 57 44 60 60 65 53 122 95 501
2022/20231.599 154 138 35 236 252 230 117 152 166 6 73 40
2023/2024956 79 88 45 25 101 187 27 85 35 25 28 231
2024/20253.531 76 79 275 142 447 302 117 159 679 385 494 376
2025/202610.539 999 379 835 1.331 1.489 715 1.331 573 970 1.091 563 263
2026/2027266 266 0 0 0 0 0 0 0 0 0 0 0
Totale 26.001